We skip to work: alternative splicing in normal and malignant myelopoiesis

Leukemia
Alex C H WongJustin J-L Wong

Abstract

Alternative splicing expands the transcriptome thereby promoting protein diversity. It governs critical cellular processes such as differentiation, proliferation and apoptosis in a tissue-specific manner. Aberrant splicing consequent to mutations in splicing factors and disruption of isoform ratios in key regulatory genes provides an important contribution to the pathogenesis of the myelodysplastic syndromes and myeloid leukemia. We review here the central role of alternative splicing in regulating myelopoiesis, and provide clear examples of how global splicing disruption or specific aberrant splicing events might promote leukemogenesis. We discuss the growing number of mechanistic links between epigenetic factors and alternative splicing. Finally, we address the potential utility of alternatively spliced isoforms as biomarkers and the development of novel therapies that modulate alternative splicing in myeloid and other malignancies.

References

Mar 11, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Kimberly J PayneGay M Crooks
Jul 31, 2003·Molecular Cell·Melissa S Jurica, Melissa J Moore
Jul 2, 2005·Molecular Cell·Christian Schwerk, Klaus Schulze-Osthoff
Mar 7, 2006·Nature Immunology·Toshimi YoshidaKatia Georgopoulos
Apr 19, 2006·International Journal of Cancer. Journal International Du Cancer·Mandy WagnerIngo Tamm
Jun 23, 2006·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Autumn MassielloCharles E Chalfant
Aug 22, 2006·Neuromuscular Disorders : NMD·G McCloreyS D Wilton
Oct 2, 2008·The Journal of Biological Chemistry·Kristine O'BrienMelissa J Moore
Nov 4, 2008·Nature·Eric T WangChristopher B Burge
Oct 8, 2009·Cancer Research·Matthias SchaeferFrank Lyko
Aug 14, 2010·Cell·Michael J MoorePamela A Silver
Dec 18, 2010·Genome Research·Joanna Y IpBenjamin J Blencowe
Feb 12, 2011·PloS One·Jarmila HnilicováDavid Staněk
Jul 19, 2011·World Journal of Biological Chemistry·Olivia L FrancisKimberly J Payne
Sep 13, 2011·Nature·Kenichi YoshidaSeishi Ogawa
Sep 17, 2011·Nature Reviews. Genetics·Auinash Kalsotra, Thomas A Cooper
Oct 15, 2011·The New England Journal of Medicine·E PapaemmanuilUNKNOWN Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium
May 12, 2012·Nature·Dan DominissiniGideon Rechavi
Jul 24, 2012·Trends in Molecular Medicine·Ravi K Singh, Thomas A Cooper
Aug 25, 2012·Blood·Manja MeggendorferSusanne Schnittger
Mar 15, 2013·ACS Chemical Biology·Yang Gao, Kazunori Koide
Mar 26, 2013·Chromosoma·Zhihong Zhou, Xiang-Dong Fu
Dec 1, 2011·Therapeutic Advances in Hematology·Kara L Davis
Aug 3, 2013·Annals of Neurology·Jerry R MendellUNKNOWN Eteplirsen Study Group
Aug 29, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ferry A L M EskensJosep Tabernero
Sep 14, 2013·Blood·Elli PapaemmanuilUNKNOWN Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium
Nov 29, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sophia AdamiaJames D Griffin
Jan 21, 2014·Nucleic Acids Research·Harold PimentelJohn G Conboy
May 16, 2014·Human Gene Therapy·Petra DistererBernard Khoo

❮ Previous
Next ❯

Citations

Aug 18, 2018·Wiley Interdisciplinary Reviews. RNA·Xiaolei Liu, Peter S Klein
Apr 2, 2019·Nucleic Acids Research·Carmen Mora GallardoKarel H M van Wely
Aug 14, 2020·Experimental Biology and Medicine·Emel RothzergSulev Kõks
Jan 28, 2020·The Journal of Clinical Investigation·Livius Penter, Catherine J Wu
Aug 21, 2020·RNA Biology·Adel B AlharbiJohn Ej Rasko
Sep 20, 2018·F1000Research·Kirsten A Reimer, Karla M Neugebauer
Apr 5, 2020·Journal of Clinical Medicine·Isaac Hurtado-GuerreroBegoña Oliver-Martos
Aug 12, 2018·International Journal of Molecular Sciences·Zaira Ianniello, Alessandro Fatica
May 30, 2020·Cancer Cell International·Yanni DingMin Yang
Aug 15, 2020·Frontiers in Genetics·Xiang-Yang ShaoLei Zheng
May 16, 2020·International Journal of Molecular Sciences·Konstantin SchuschelJessica I Hoell
Oct 30, 2020·International Journal of Molecular Sciences·Lourdes Cruz-GarciaChristophe Badie
Jun 29, 2021·Nucleic Acids Research·Adel B AlharbiJohn E J Rasko

❮ Previous
Next ❯

Methods Mentioned

BETA
MDS
genetic knockout
xenograft
histone acetylation
acetylation
reverse transcription quantitative PCR
xenografts

Clinical Trials Mentioned

NCT02841540

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Alternative splicing

Alternative splicing a regulated gene expression process that allows a single genetic sequence to code for multiple proteins. Here is that latest research.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.